Skip to main content

SurroMed, Japanese Genomics Firm to Develop, Sell Biomarkers

NEW YORK, July 31 - SurroMed and Japanese genomics service company MediBic will co-develop biomarkers for drug discovery, the companies said today.


Terms of the deal also call for Tokyo-based MediBic to exclusively sell the biomarkers in Japan.

"We are confident that [MediBic's] ... record and their longstanding relationships will enable us to expand the market in Japan," said SurroMed CEO Gordon Ringold.

SurroMed's biomarker-discovery program pairs sample-preparation techniques with mass spectrometry. SurroMed then uses bioinformatics tools to analyze and mine the data.

MediBic has "relationships" with more than 20 Japanese pharmaceutical and biotechnology companies, according to the company.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.